Generic Name and Formulations:
Sodium hyaluronate 20mg/2mL; soln for intra-articular inj.
Indications for HYALGAN:
Osteoarthritis of the knee in patients who have failed nonpharmacologic therapy and analgesics (eg, acetaminophen).
Prior to treatment: remove joint effusion (use separate syringe), if present; and give local anesthetic (eg, lidocaine) by SC inj. Inject 2mL intra-articularly in each affected knee weekly for 5 weeks. Use separate syringes for each knee.
Infection or skin disease at inj site.
Treatment cycle <3 injections: not recommended. Avian protein, feather, egg allergy. Avoid strenuous activity within 48hrs after injection. Pregnancy. Nursing mothers.
Avoid disinfectants with quaternary ammonium salts. Concomitant other intra-articular injectables: not recommended.
Inj site pain, local reactions, transient knee inflammation.
Single-use vials—1; Single-use prefilled syringes—1
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Clinicians May Be Overtreating Older Patients With Diabetes
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Hormonal Contraceptives May Adversely Affect Psychological Health in Adolescent Girls
- Obesity Can Negatively Effect Liver in Children as Young as 8
- Recommendations Developed on Gender Equity in Medicine
- Intensive Lifestyle Interventions Cut Long-Term Disability in Type 2 Diabetes